The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.

A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.

Researchers reporting in ACS Nano have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.

The findings, published in the Journal of Medical Microbiology, show the rapid molecular test called N1-STOP-LAMP, is 100% accurate in diagnosing samples containing SARS-CoV-2 at high loads.

A novel flavivirus identification test that is both fast and sensitive has been validated in Brazil by Mariana Sequetin Cunha and collaborators at the Adolfo Lutz Institute.

University of Queensland researchers have developed biosensors that use nanoengineered porous gold which more effectively detect early signs of disease, improving patient outcomes.

Testing is essential to help stop the spread of the COVID-19 virus.

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

Cell biologists have developed a method for SARS-CoV-2 testing that delivers results around ten times faster than current tests.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.

Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein.

A recent preprint study published in medRxiv, indicates that there is a rapid decline in the levels of SARS-CoV-2 neutralizing antibodies during the weeks following initial infection.

After only a few days caring for critically ill COVID-19 patients at the start of the outbreak in New York City, Aakriti Gupta, MD, realized that this was much more than a respiratory disease.

Now, a collaborative team have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients.

COVID-19 screening can soon be conducted directly at various testing stations, and patients can get their test results in about an hour from the time they get a nasal swab.

How the mass spectrometry works in biopharmaceutical development?

Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

The Rogers group and researchers at Shirley Ryan AbilityLab introduced a novel wearable device and set of data algorithms specifically tailored to catch early signs and symptoms associated with COVID-19 and to monitor patients as the illness progresses.

The Danaher Corp. company received emergency use authorization for its Access SARS-CoV-2 IgG test.

Sera Prognostics is developing a biomarker test for?predicting very preterm birth.